Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis

Abstract

PAL was more effective than the other 5-HT(3)R in preventing acute and delayed CINV in patients receiving MoHE treatments, regardless of the use of concomitant corticosteroids.

Efficacy of palonosetron for preventing postoperative nausea and vomiting: a systematic review and meta-analysis

“…Previous meta-analyses showed that other 5-HT 3 RAs, including ondansetron, granisetron, and ramosetron, had similar rates of adverse effects when used for the prevention of PONV, 10,38 and use of palonosetron did not result in a higher incidence of adverse effects compared with other 5-HT 3 RAs for the prevention of chemotherapy-induced nausea and vomiting. 18,19 Nevertheless, we cannot easily draw a conclusion regarding the safety profile of palonosetron because the studies in this meta-analysis did not report the incidence of all common adverse effects or any rare but severe adverse events.…”

“…Méthodes Nous avons effectué une recherche systématique dans les bases de données MEDLINE Ò , EMBASE TM , le Registre central Cochrane des essais cliniques contrô lés et Web of Science Ò pour identifier les essais randomisés contrô lés qui ont abordé la comparaison de l'efficacité antiémétique dans les 24 premières heures suivant une chirurgie, du palonosétron et de l'ondansétron administrés à titre prophylactique. Les principaux critères d'évaluation étaient le pourcentage de participants éprouvant des nausées postopératoires (NPO), des vomissements postopératoires (VPO) ou les deux, dans la période précoce (0-6 heures) ou tardive (6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24) Postoperative nausea and vomiting (PONV), the big ''little problem'', 1 is the most common postoperative medical problem. From the perspective of both patients and healthcare providers, prophylaxis of PONV is equally as important as postoperative analgesia.…”

“…Importantly, preliminary studies have already shown that palonosetron is safer and more effective than other 5-HT 3 RAs in preventing chemotherapy-induced nausea and vomiting, although this requires more rigorous confirmation. 18,19 In consideration of the above, we conducted this systematic review and meta-analysis to investigate whether the recommended palonosetron dose (0.075 mg iv) 20 has better efficacy than ondansetron (C 4 mg iv), a widely used first-generation 5-HT 3 RA, for the prophylaxis of nausea and vomiting during the first 24 hr following surgery.…”

Efficacy of Bifidobacterium Tetragenous Viable Bacteria Tablets for Cancer Patients with Functional Constipation

“…Chemotherapy-induced nausea and vomiting (CINV) is a common side effect of chemotherapy for many cancer patients (Botrel TE et al, 2011;Guo-Li Wei et al, 2013). CINV may lead to discontinuation of treatment, decrease quality of life of patients.…”

“…So, preventing CINV during chemotherapy is important and 5-HT3 receptor antagonists are (5-HT3-RA) widely used as antiemetics in clinical (Claudio Faria et al, 2014). But one side effect of the 5-HT3 receptor antagonists is constipation, because the 5-HT3 receptor antagonists (5-HT3-RA) prevent the gastrointestinal peristalsis, at the same time (Botrel et al, 2011;Faria et al, 2013). The 5-HT3 receptors antagonists affect GI vagal afferents to inhibit the vomiting reflex, gastric distension and delaye gastric emptying (Andrews et al, 1988;Yoshioka et al, 1990;Horn et al, 2004;Badary et al, 2006).…”